TITAN PHARMACEUTICALS AND INDEGENE ENTER INTO PROBUPHINE CO-PROMOTION

TITAN PHARMACEUTICALS AND INDEGENE ENTER

INTO PROBUPHINE CO-PROMOTION PARTNERSHIP

SOUTH SAN FRANCISCO, CA - June 24,

2020 - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that

it has entered into a co-promotion partnership with Indegene Inc. to establish multichannel digital marketing programs throughout

the United States and expand the capabilities for the engagement of health care providers ("HCPs") who are eligible

to prescribe Titan's Probuphine (buprenorphine) implant.

Indegene is a leading healthcare solutions

company with a unique blend of life sciences domain expertise and state-of-the-art technology capabilities that will complement

and help accelerate the build out of the current commercial operations at Titan. Under the terms of the renewable four-year agreement,

Indegene's sophisticated multichannel marketing tools, predictive analytics, webinars and social media campaigns will be used along

with its dedicated tele-representatives to help expand the universe of Probuphine Risk Evaluation and Mitigation Strategy ("REMS")-certified

HCPs and enable further expansion of maintenance treatment with Probuphine for eligible Opioid Use Disorder ("OUD")

patients. Titan will continue its ongoing commercial efforts with its field sales and medical liaison personnel who will also provide

support to Indegene as needed. Titan will be responsible for all training of HCPs, administration of the REMS program and regulatory

"This partnership with Indegene further

strengthens and expands our Probuphine commercial operations, especially with the COVID-19-related restrictions that have limited

in-person HCP outreach capabilities," said Titan's President and CEO, Sunil Bhonsle. "Indegene brings a wealth of business

expertise and experience in the digital arena working globally with large and small pharmaceutical companies that is invaluable

in today's changing environment. This partnership accelerates the expansion of our capabilities to potentially achieve our

goals and enable access to Probuphine for eligible patients suffering from OUD, especially at a time when a six-month maintenance

treatment option could be very important in minimizing frequent direct contact."

Please see Probuphine Full Indication and

Important Safety Information and Boxed Warning below, and link below to Full Prescribing Information.

"We are looking forward to partnering

with Titan using our proven AI-driven Next Generation Commercialization Platform," said Gaurav Kapoor, Executive Vice President

of Indegene Inc. "This partnership comes at a meaningful time, when the COVID-19 pandemic is exacerbating the opioid crisis

while limiting direct engagement with the HCPs that treat OUD patients. I believe the new normal' model in pharma

commercial operations will start relying just as much on digital programs with remote representatives, as field representatives

providing face-to-face interaction. We at Indegene are making significant investments to be at the forefront of this transition

and are excited to see Titan embrace this innovative approach."

Probuphine is the only subdermal implant

designed to deliver buprenorphine continuously for six months following insertion.

Probuphine was developed using ProNeura ,

the continuous drug delivery system developed by Titan that consists of a small, solid implant made from a mixture of ethylene-vinyl

acetate and a drug substance. The resulting construct is a solid matrix that is placed subdermally, normally in the upper inner

arm in an outpatient office procedure and removed in a similar manner at the end of the treatment period. The U.S. Food and Drug

Administration ("FDA") approved Probuphine in May 2016, and it is the first and only buprenorphine implant available

for the maintenance treatment of opioid addiction in eligible patients.

IMPORTANT SAFETY INFORMATION INCLUDING INDICATION AND BOXED

PROBUPHINE is an implant that contains the medicine buprenorphine.

PROBUPHINE is used to treat certain adults who are addicted to (dependent on) opioid drugs (either prescription or illegal). PROBUPHINE

is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical

stability on low-to-moderate doses (doses no more than 8 mg per day) of a buprenorphine-containing product.

PROBUPHINE is part of a complete treatment program that also

includes counseling and behavioral therapy.

It is not known if PROBUPHINE is safe or effective in children

less than 16 years of age.

WARNING: COMPLICATIONS FROM INSERTION

AND REMOVAL OF PROBUPHINE

See Full Prescribing Information for

complete Boxed Warning

Serious complications may happen from insertion and removal

of PROBUPHINE, including:

Call your healthcare provider right away if:

If the implant comes out by itself, keep it away from others,

especially children, as it may cause severe difficulty in breathing and possibly death.

Because of the risk of complications of, migration, protrusion,

expulsion and nerve injury with insertion and removal of PROBUPHINE, it is only available through a restricted program called the

PROBUPHINE REMS Program. Healthcare providers who prescribe and/or insert PROBUPHINE must be certified with the program by enrolling

and completing live training.

Implants may be difficult to locate if inserted too deeply,

if you manipulate them, or if you gain significant weight after insertion. Your healthcare provider may do special procedures or

tests, or refer you to a surgical specialist to remove the implants if they are difficult to locate.

The medicine in PROBUPHINE can cause serious and life-threatening

problems, especially if you take or use certain other medicines or drugs. Call your healthcare provider right away or get emergency

Feel faint or dizzy, have mental changes such as confusion,

slower breathing than you normally have, severe sleepiness, blurred vision, problems with coordination, slurred speech, cannot

think well or clearly, high body temperature, slowed reflexes, feel agitated, stiff muscles or have trouble walking.

These can be signs of an overdose or other serious problems.

Coma or death can happen if you take anxiety medicines or benzodiazepines,

sleeping pills, tranquilizers, or sedatives, antidepressants, or antihistamines, or drink alcohol during treatment with PROBUPHINE.

Tell your healthcare provider if you are taking any of these medicines or if you drink alcohol.

Who should not use PROBUPHINE?

Do not use PROBUPHINE if you are allergic to buprenorphine or

any of its ingredients, this includes buprenorphine hydrochloride and the inactive ingredient ethylene vinyl acetate or EVA.

PROBUPHINE may not be right for you. Before starting PROBUPHINE

tell your doctor about all of your medical conditions, including:

Trouble breathing or lung problems, an enlarged prostate gland

(men), a head injury or brain problem, problems urinating, a curve in your spine that affects your breathing, liver problems, gallbladder

or adrenal gland problems, Addison's disease, low thyroid hormone levels (hypothyroidism), a history of alcoholism, a history

of keloid formation, connective tissue disease (such as scleroderma), or history of MRSA infections, mental problems such as hallucinations,

an allergy to numbing medicines or medicines used to clean your skin, are pregnant or plan to become pregnant or are breastfeeding

or plan to breastfeed.

Tell your doctor about all the medicines you take, including

prescription and over-the-counter medicines, vitamins and herbal supplements.

What should I avoid while being treated with PROBUPHINE?

What are the possible side effects of PROBUPHINE?

PROBUPHINE can cause serious side effects, including:

Tell your healthcare provider if you develop any of the symptoms

Common side effects of PROBUPHINE include: Headache,

nausea, toothache, constipation, depression, vomiting, back pain, mouth and throat pain.

Common risks with the minor surgical procedure: Itching,

pain, irritation, redness, swelling, bleeding, or bruising at the insertion or removal site. Scarring around the insertion site.

Please read Full Prescribing Information,

including BOXED WARNING regarding IMPLANT MIGRATION, PROTRUSION, EXPULSION and NERVE DAMAGE ASSOCIATED WITH INSERTION

Titan encourages you to report negative

side effects of prescription drugs to the FDA. You can visit www.fda.gov/safety/medwatch/ or call 1-800-FDA-1088.

About Indegene, Inc.

Indegene is a leading global healthcare